Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Moderna Rallies On Merck Collaboration: Can Drugmaker Replace COVID Vaccine Revenue?

In late 2020, when the world was searching for a vaccine or cure for COVID-19, the price action in Moderna Inc (NASDAQ: MRNA) was discussed frequently on Benzinga's PreMarket Prep show.

Benzinga

FDA authorizes COVID omicron boosters for kids 5 and up

COVID-19 vaccine makers Pfizer Inc. and Moderna Inc. received U.S. regulatory clearances for their omicron-targeted boosters for children as young as 5.

Tribune News Service

Why T2 Biosystems Shares Are Trading Lower By Over 28%, Here Are 41 Stocks Moving In Wednesday's Mid-Day Session

Gainers Code Chain New Continent Limited (NYSE: CCNC) shares jumped 74% to $0.2868 after declining around 14% on Tuesday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Omicron boosters for kids 5-12 are cleared by the CDC

Tweaked boosters rolled out for Americans 12 and older last month, modified to target today's most common and contagious variant. The latest move may expand protection before an expected winter wave.

WEKU

FDA clears updated COVID boosters for kids as young as 5

The U.S. is about to offer updated COVID-19 booster shots to kids as young as 5

The Independent UK

Africa overcomes the odds to produce its own Covid vaccines

Set on redressing vaccine inequality between rich and poor nations, a South African consortium is taking on pharmaceutical giants in its quest to produce Africa's first homegrown mRNA Covid-19 vaccine and share it with the global south.

Radio France Internationale

Australian adults can now get Moderna's Omicron COVID-19 booster. Here's what we know

How can we get the new two-in-one COVID booster, what's in it, and how much protection does it provide?

ABC News

Read news from The Economist, FT, and more,
with one subscription

Looking At Moderna's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

‘Like copying a Louis Vuitton handbag’: big pharma hits out at Africa’s replica Covid vaccine

Knowledge-sharing hub in Cape Town reverse engineered the Moderna vaccine, but future of the initiative to reduce inequity remains unsure

The Guardian - UK

The new Covid wave - what you should know from symptoms to facemasks and flu risk

Covid cases have been increasing ahead of the winter flu season.

Daily Record

Check Out What Whales Are Doing With MRNA

Benzinga

This Is What Whales Are Betting On Moderna

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 25 strange trades.

Benzinga

iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26

Bloomberg

Benzinga

No, AI won't change Big Pharma

Claims that artificial intelligence will change the way drugs are made are almost certainly overblown. Here’s why

Salon

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Moderna seeks emergency authorization for COVID booster for children

The application for children ages 6 months to under 6 years is expected to be completed later this year.

Los Angeles Times

Moderna vs. Pfizer: Is it OK to mix and match the updated COVID-19 booster shots?

LOS ANGELES — As residents prepare to roll up their sleeves for a third, fourth or even fifth dose of COVID-19 vaccine, some may be wondering: Do I need to stick with the same brand, or is it safe to mix it up?

Benzinga

Pharma Giants Moderna And Novavax Trend Lower In This Pattern: What's Going On?

Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.

Tribune News Service

Shortages of Moderna COVID-19 boosters seen in US

Some of the nation's pharmacies are reporting shortages of Moderna Inc.’s new bivalent booster shot for COVID-19 as one factory used in producing the vaccine remains offline following a safety inspection.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

Canadian scientists made life-saving contributions during the COVID-19 pandemic

This year, the Nobel Prize in physiology or medicine will be awarded on Oct. 3. Canada will be in the spotlight again, thanks to Canadian scientists’ involvement with mRNA vaccine development.

Benzinga

Check Out What Whales Are Doing With MRNA

Benzinga

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 35 strange trades.

Reuters

Take whatever COVID booster you can get, says head of EU drugs watchdog

People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview ahead of an expected autumn rise in infections.

Benzinga

Top Financial Stories Wednesday, September 14: Multiple Antitrust Setbacks For Google, Bitcoin Crashes, Visa Finds New Gun Control System Ineffective And More…

Reuters

Salon

Is the new omicron vaccine worth it?

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Tribune News Service

Commentary: Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.